Medication-assisted treatment (MAT) combines FDA-approved medication with counseling and behavioral therapy to treat opioid use disorder (OUD) and alcohol use disorder (AUD). The medication reduces cravings and withdrawal symptoms. The counseling addresses what drives the substance use in the first place.
Everything below applies to adults in the United States, and covers the federal rules that changed between 2022 and 2026. Silver Lining Recovery is an outpatient provider in Huntington Beach, California, and our structured intensive outpatient care runs alongside whatever medication plan a prescriber sets. We do not offer detox, inpatient, or residential care on site.
Key Takeaways
- MAT is medication plus therapy, not medication alone. The FDA has approved three medications for opioid use disorder and three for alcohol use disorder, and all of them are intended to be paired with counseling.
- The evidence is strongest for opioid use disorder. In a study of 17,568 overdose survivors, methadone was associated with 59% lower opioid overdose mortality and buprenorphine with 38% lower, over 12 months.
- Access rules changed substantially between 2022 and 2026. The federal X-waiver was eliminated in December 2022, and a 2024 rule expanded take-home methadone and telehealth starts.
- Where you get MAT depends on the medication. Methadone for OUD is dispensed only through certified opioid treatment programs, while buprenorphine and naltrexone can be prescribed in ordinary outpatient settings.
- MAT has no fixed end date. How long someone stays on medication is a clinical decision made with a prescriber, not a countdown.
Wondering how medication fits with therapy in a program that works around your job or classes? Verify your insurance benefits or call (866) 681-0927 to talk it through with a real admissions counselor.
How medication-assisted treatment works
Opioid and alcohol dependence change how the brain handles reward, stress, and craving. Those changes do not undo themselves the day someone decides to stop. Cravings and withdrawal are physical symptoms, not proof of weak willpower.
MAT medications act on that biology directly. Some occupy the same receptors as opioids without producing the same high. Others block the effect of a substance, or make drinking physically unpleasant.
Steadying the biology is what makes the rest of treatment possible. Someone whose cravings have quieted can sit through a therapy group, hold down a job, and do the harder work underneath. Medication buys the room; therapy uses it.
The evidence behind this is not marginal. Research reported by the National Institutes of Health, drawn from 17,568 Massachusetts adults who survived an opioid overdose, found that methadone treatment was associated with 59% lower opioid overdose mortality over the following year, and buprenorphine with 38% lower.
The same study found fewer than one in three survivors received any medication at all in that year. The gap between what works and what people actually get is the reason access rules have been rewritten repeatedly since.
The medications used in MAT
Six medications carry FDA approval across the two conditions MAT treats. Which one fits depends on the diagnosis, the person’s history, other medications, and where they can realistically get care.
| Medication | Treats | How it works | Where it is provided | Notes |
|---|---|---|---|---|
| Buprenorphine | Opioid use disorder | Partial opioid agonist, eases withdrawal without full opioid effect | Office-based outpatient settings and telehealth | Often combined with naloxone; no special waiver needed since 2023 |
| Methadone | Opioid use disorder | Full opioid agonist, prevents withdrawal at a stable dose | Certified opioid treatment programs (OTPs) only | Federally restricted dispensing; take-home rules expanded in 2024 |
| Naltrexone (oral) | Opioid and alcohol use disorder | Blocks opioid receptors, reduces alcohol reward | Standard outpatient settings | Requires a period free of opioids before starting |
| Naltrexone (extended-release injection) | Opioid and alcohol use disorder | Same mechanism, monthly injection | Standard outpatient settings | Removes daily adherence as a variable |
| Acamprosate | Alcohol use disorder | Helps normalize brain chemistry disrupted by chronic drinking | Standard outpatient settings | Taken three times daily; used in maintenance |
| Disulfiram | Alcohol use disorder | Causes an unpleasant reaction if alcohol is consumed | Standard outpatient settings | Depends heavily on consistent daily adherence |
Notice the split in the fourth column. Methadone for opioid use disorder sits under a separate federal licensing regime, which is why someone can get buprenorphine from a primary care office but has to attend a certified program for methadone.
No FDA-approved medication exists for meth or other stimulants. Care for stimulant use leans on behavioral methods instead, such as contingency management and talk therapy.
MAT, MOUD, and why the wording is shifting
Many clinicians and agencies now write MOUD, short for medications for opioid use disorder, instead of MAT when opioids are the subject. Both describe the same care.
The newer term exists because “assisted” implied medication was a helper to the real treatment. For opioid use disorder specifically, medication is a primary treatment in its own right. MAT remains the broader term when alcohol use disorder is included.
What medication-assisted treatment is not
Three misconceptions come up constantly, and each one keeps people out of treatment.
It is not swapping one addiction for another. A steady, supervised dose does not create the cycle of getting high, crashing, and chasing more that defines a substance use disorder. Someone stable on buprenorphine can drive, parent, and hold a job.
Not sure which program is right for you? Our admissions team is here to help — 100% confidential, no obligation.
Get Help Today →It is not a shortcut past therapy. Medication addresses the physical layer. It does nothing about the trauma, the dual diagnosis care for co-occurring conditions, or the relationships and habits that surround the substance use.
It is not automatically permanent. Some people take medication for months, others for years. Stopping is a decision made with a prescriber based on stability, and tapering too early is associated with return to use.
What changed between 2022 and 2026
Anyone who looked into MAT before 2023 and found it hard to access should look again. Four federal changes in four years reshaped who can prescribe these medications, how patients receive them, and whether an in-person visit is required at all.
| Change | When | What it means in practice |
|---|---|---|
| X-waiver eliminated (Consolidated Appropriations Act, 2023, §1262) | Signed December 29, 2022 | Any DEA-registered prescriber can prescribe buprenorphine for OUD, with no patient caps |
| MATE Act training requirement | Registrations on or after June 27, 2023 | One-time 8-hour training for DEA registrants on treating substance use disorders |
| 42 CFR Part 8 final rule | Effective April 2, 2024; compliance October 2, 2024 | Take-home methadone expanded; telehealth starts allowed; one-year history requirement removed |
| Telehealth prescribing flexibilities | Extended through December 31, 2026 | Controlled medications, including buprenorphine, can be prescribed without a prior in-person visit |
| Practitioner definition broadened | April 2024 | More licensed professionals may order and dispense MAT medications within OTPs |
The waiver requirement is gone
For two decades, prescribing buprenorphine required a special DATA-2000 registration, known as the X-waiver, and imposed caps on how many patients a prescriber could treat. Section 1262 of the Consolidated Appropriations Act, 2023 removed that requirement when it was signed on December 29, 2022.
Any prescriber holding a standard DEA registration can now prescribe buprenorphine for opioid use disorder. The patient caps are gone too. A separate one-time 8-hour training requirement applies to DEA registrants at their next registration or renewal on or after June 27, 2023.
The 2024 rule rewrote opioid treatment programs
The Substance Abuse and Mental Health Services Administration (SAMHSA) finalized changes to 42 CFR Part 8, the regulation governing certified opioid treatment programs. The rule took effect April 2, 2024, with a compliance date of October 2, 2024.
Several changes matter to patients directly. Stable patients may receive up to 28 days of take-home methadone, and less stable patients up to 14 days, based on the treating provider’s clinical judgment. Take-home eligibility can now begin at entry rather than after months of daily attendance.
Patients can now start buprenorphine over a phone or video call, and methadone over video, when the provider judges the evaluation good enough. Phone-only starts are barred for methadone because it carries a higher sedation risk.
One more change removed a long-standing barrier. Admission no longer requires a documented one-year history of opioid addiction. Someone with moderate to severe OUD, or at high risk of recurrence or overdose, can qualify.
Telehealth prescribing, and its expiration date
DEA and HHS extended the telemedicine flexibilities that allow controlled medications to be prescribed without a prior in-person visit, currently through December 31, 2026. Buprenorphine falls within that scope.
Treat that date as real. The flexibilities have been extended several times rather than made permanent, so anyone relying on remote prescribing should ask their provider what happens if the rules revert. Therapy delivered remotely is unaffected, which is why virtual intensive outpatient sessions remain a stable option regardless of prescribing rules.
What this means if you are looking now
The bottleneck has moved. Finding a prescriber is easier than it was in 2022, and the harder question now is what wraps around the medication.
Medication without therapy leaves the underlying drivers untouched, and it is a known pattern behind the warning signs of opioid relapse. Whichever prescriber you work with, the surrounding treatment is worth choosing deliberately.
Where MAT fits alongside outpatient treatment
MAT is not a level of care. It is a component that runs alongside one, and the level of care determines how much structure and clinical contact comes with it.
Someone needing daily clinical contact may start in a partial hospitalization program schedule before stepping down. Someone balancing treatment against a job may do better with intensive outpatient care several evenings a week. Standard outpatient suits people who are stable and need continued support.
Ready to take the first step toward recovery? We’re available 24/7.
Withdrawal management is worth asking about directly. Detox is a separate medical service, and a program that offers outpatient therapy may not offer it. Ask whether they handle withdrawal on site or set it up with an outside provider.
Veterans and service members often carry a different mix, with service-related pain and trauma layered under the substance use. A dedicated veterans and active military track treats that combination head on rather than as a footnote.
How to know whether MAT might fit
A clinician makes this determination after an assessment. These patterns tend to point toward a medication conversation:
- Repeated attempts to stop opioids or alcohol that ended in withdrawal
- Cravings intense enough to override every other plan
- A prior overdose, or use patterns carrying overdose risk
- Chronic pain alongside opioid dependence
- Anxiety, depression, PTSD, or bipolar disorder occurring with substance use
- Treatment episodes that worked while structured and unravelled afterward
MAT is not right for everyone, and it is not the only path. Some people do well with therapy and peer support alone. The point of an assessment is finding out which category you fall into rather than guessing.
Frequently asked questions
Is MAT just replacing one drug with another?
No. Prescribed medication at a controlled, supervised dose does not produce intoxication or compulsive seeking. Taking a medication as directed under clinical supervision is a different thing from active substance use.
Which medications are used in MAT?
Buprenorphine, methadone, and naltrexone for opioid use disorder. Naltrexone, acamprosate, and disulfiram for alcohol use disorder. Methadone for OUD is dispensed only through certified opioid treatment programs.
How long does MAT last?
There is no set duration. Some people take medication for months and others for years, and the decision to taper belongs to the patient and prescriber together. Stopping too early is associated with return to use.
Do you still need an X-waiver to prescribe buprenorphine?
No. That requirement ended in December 2022. Any prescriber with a standard DEA registration can prescribe buprenorphine for opioid use disorder, with no patient limits.
Can MAT be started through telehealth?
Under the flexibilities currently extended through December 31, 2026, buprenorphine can be prescribed without a prior in-person visit. The 2024 SAMHSA rule also permits telehealth initiation within opioid treatment programs, with audio-visual required for methadone.
Are there side effects?
Every one of these medications has possible side effects, and they differ by medication and by person. A prescriber reviews the risks beforehand and monitors the response. Disclose all other medications and conditions, including pregnancy.
Can you work while taking MAT medication?
Generally yes, once stabilized. These medications are prescribed specifically so people can function normally, and outpatient programs with evening or virtual scheduling exist for exactly that reason.
Getting started
The useful next step is an assessment, not a decision about medication. An assessment establishes the diagnosis, the level of care, and whether medication belongs in the plan, and none of that can be settled from a webpage.
Silver Lining Recovery treats addiction and mental health on an outpatient basis in Huntington Beach, serving Orange, Los Angeles, and Riverside counties. Every assessment is free and private. Therapy options include CBT, DBT, and EMDR.
Ready to talk to someone? Contact our admissions team or Call (866) 681-0927 to start with a free, confidential assessment.
This article is for general information and is not a substitute for medical advice, diagnosis, or treatment. Talk with a qualified healthcare provider about your situation. If you are in crisis, call or text 988 to reach the Suicide and Crisis Lifeline.
